Article | October 24, 2022

Unpacking IRB Innovations For Decentralized Clinical Trials

Source: Advarra

By James Riddle, MCSE, CIP, CPIA, CRQM, VP of Research Services & Strategic Consulting

GettyImages-1278681737 decentralized trials

In the context of decentralized clinical trials (DCTs), we have seen an explosion of new devices and apps interacting with participants and collecting information throughout a trial, all with the participant never setting foot in a traditional clinical research site.

Ethical oversight committees (like Advarra’s institutional review board [IRB]) continue to innovate to keep pace with the rapid changes and evolution of research conduct. Study designs flexibly incorporating telepresence visits, remote home visits, and other decentralized clinical trial technologies and innovations provide improved participant engagement.

IRBs must become familiar with this technology in order to appropriately consider how such innovations impact the participant experience and a given study’s risk/benefit assessment. It’s also important for IRBs to understand how their review requirements can impact overall study efficiencies.

This blog highlights how IRBs can simplify review of electronic patient reported outcome (ePRO) and electronic clinical outcome assessment (eCOA) materials to streamline study startup without impacting the review quality.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader